Pfizer’s IBRANCE fails to meet primary endpoint in PENELOPE-B breast cancer trial

The latest results from Pfizer’s Phase 3 PENELOPE-B clinical trial have cast a shadow over the potential of IBRANCE (palbociclib) in the treatment of early-stage ... Read More